Cargando…
Biosimilars Have Arrived: Rituximab
A biosimilar is a biologic product that is highly similar to a licensed biologic (“originator”) such that there are no clinically meaningful differences in safety, purity, or potency between the biosimilar and the originator. As patent protection and data exclusivity for the biologic rituximab expir...
Autores principales: | Greenwald, Maria, Tesser, John, Sewell, K. Lea |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5885398/ https://www.ncbi.nlm.nih.gov/pubmed/29765782 http://dx.doi.org/10.1155/2018/3762864 |
Ejemplares similares
-
The arrival of biosimilar monoclonal antibodies in oncology: clinical studies for trastuzumab biosimilars
por: Barbier, Liese, et al.
Publicado: (2019) -
Biosimilars and the extrapolation of indications for inflammatory conditions
por: Tesser, John RP, et al.
Publicado: (2017) -
Biologicals and Biosimilars in Hematology: The Case of Rituximab
por: Vulto, Arnold G.
Publicado: (2019) -
Rituximab biosimilars open new horizons in immunotherapy
por: Jaeger, Ulrich
Publicado: (2017) -
Efficacy and safety of rituximab biosimilar in refractory lupus
por: Pongtarakulpanit, Nantakarn, et al.
Publicado: (2020)